Search Result

Results for "

NOX1 NAD(P)H oxidase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NADPH Oxidase (15) Ferroptosis (2) p38 MAPK (1) Reactive Oxygen Species (ROS) (2) Reference Standards (4) TGF-β Receptor (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (8) Endocrinology (1) Inflammation/Immunology (6) Metabolic Disease (7) Neurological Disease (5)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Targets Recommended: NADPH Oxidase Amino Acid Oxidase Lysyl Oxidase Glycolate Oxidase Aldehyde Oxidase (AO) Xanthine Oxidase Monoamine Oxidase Protoporphyrinogen IX oxidase VAP-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12298

Setanaxib Maximum Cited Publications 30 Publications Verification GKT137831; GKT831	NADPH Oxidase Ferroptosis	Cardiovascular Disease
Setanaxib (GKT137831) is a selective NADPH oxidase (NOX1/4) inhibitor with K_is of 140 and 110 nM, respectively.

HY-12805

ML171 15+ Cited Publications 2-Acetylphenothiazine; 2-APT	NADPH Oxidase	Cardiovascular Disease
ML171 (2-Acetylphenothiazine;2-APT) is a potent and selective NADPH oxidase 1 (Nox1) inhibitor that blocks Nox1-dependent ROS generation, with an IC₅₀ of 0.25 μM in HEK293-Nox1 confirmatory assay.

HY-120801

APX-115 2 Publications Verification Ewha-18278	NADPH Oxidase	Metabolic Disease Inflammation/Immunology
APX-115 (Ewha-18278) is a potent, orally active pan **NADPH oxidase (Nox) inhibitor with K_i values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4**, respectively. APX-115 effectively prevents kidney injury .

HY-101499

GKT136901 4 Publications Verification	NADPH Oxidase	Neurological Disease Metabolic Disease Inflammation/Immunology
GKT136901 is a potent, selective and orally active inhibitor of **NADPH oxidase (NOX1/4), with K_i**s of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite. GKT136901 can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 also has anti-inflammatory activity .

HY-120801A

APX-115 free base 2 Publications Verification Ewha-18278 free base; Isuzinaxib free base	NADPH Oxidase	Inflammation/Immunology Endocrinology
APX-115 free base (Ewha-18278 free base) is a potent, orally active pan **NADPH oxidase (Nox) inhibitor with K_i values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4**, respectively. APX-115 free base effectively prevents kidney injury .

HY-126195

Fluoflavine ML-090	NADPH Oxidase	Neurological Disease
Fluoflavine (ML-090) is a selective *NOX1* inhibitor and reactive oxygen species inhibitor. Fluoflavine reduces reactive oxygen species production, *NOX1*-mediated downstream signaling events, and oxygen-glucose deprivation-induced retinal ganglion cell death. Fluoflavine inhibits NADPH oxidase activity and pathological retinal neovascularization induced by oxygen-induced retinopathy in the retinas of ischemic mice. Fluoflavine can be used in studies related to retinal ischemia-reperfusion injury and proliferative retinopathy .

HY-P1435

NoxA1ds	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds can be used in the study of hypertension, atherosclerosis and tumors .

HY-101499A

GKT136901 hydrochloride 4 Publications Verification	NADPH Oxidase	Neurological Disease Metabolic Disease
GKT136901 hydrochloride is a potent, selective and orally active inhibitor of **NADPH oxidase (NOX1/4), with K_i**s of 160 and 165 nM, respectively. GKT136901 hydrochloride is also a selective and direct scavenger of peroxynitrite. GKT136901 hydrochloride can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 hydrochloride also has anti-inflammatory activity .

HY-12805R

ML171 (Standard) 2-Acetylphenothiazine (Standard); 2-APT (Standard)	NADPH Oxidase Reference Standards	Cardiovascular Disease
ML171 (Standard) is the analytical standard of ML171. This product is intended for research and analytical applications. ML171 (2-Acetylphenothiazine;2-APT) is a potent and selective NADPH oxidase 1 (Nox1) inhibitor that blocks Nox1-dependent ROS generation, with an IC50 of 0.25 μM in HEK293-Nox1 confirmatory assay.

HY-12298R

Setanaxib (Standard) GKT137831 (Standard); GKT831 (Standard)	NADPH Oxidase Ferroptosis Reference Standards	Cardiovascular Disease
Setanaxib (Standard) is the analytical standard of Setanaxib. This product is intended for research and analytical applications. Setanaxib (GKT137831) is a selective NADPH oxidase (NOX1/4) inhibitor with Kis of 140 and 110 nM, respectively.

HY-148936

GLX481372	NADPH Oxidase Reactive Oxygen Species (ROS)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GLX481372 is a **NADPH Oxidase** (NOX) inhibitor. GLX481372 potently inhibits *NOX4/5* activities with IC₅₀ values of 0.68 and 0.57 μM. GLX481372 also has weak inhibitory activity against NOX1, NOX2, and NOX3, with IC₅₀ values of 7, 16 and 3.2 μM respectively. GLX481372 can inhibit ROS production. GLX481372 can be used for the researches of inflammation, cardiovascular and metabolic disease, such as diabetes .

HY-P1435A

NoxA1ds TFA	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds TFA is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds TFA inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds TFA can be used in the study of hypertension, atherosclerosis and tumors .

HY-101499AR

GKT136901 hydrochloride (Standard)	Reference Standards NADPH Oxidase	Neurological Disease Metabolic Disease
GKT136901 (hydrochloride) (Standard) is the analytical standard of GKT136901 (hydrochloride). This product is intended for research and analytical applications. GKT136901 hydrochloride is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 hydrochloride is also a selective and direct scavenger of peroxynitrite. GKT136901 hydrochloride can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 hydrochloride also has anti-inflammatory activity .

HY-101499R

GKT136901 (Standard)	Reference Standards NADPH Oxidase	Neurological Disease Metabolic Disease Inflammation/Immunology
GKT136901 (Standard) is the analytical standard of GKT136901. This product is intended for research and analytical applications. GKT136901 is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite. GKT136901 can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 also has anti-inflammatory activity .

HY-124487

GK-136901	NADPH Oxidase TGF-β Receptor Reactive Oxygen Species (ROS) p38 MAPK	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GK-136901 is an orally active, dual **Nox1/Nox4 NADPH** oxidase inhibitor with a K_i of 160 nM for *Nox1* and 165 nM for *Nox4. GK-136901 potently blocks high glucose-induced intracellular reactive oxygen species production, p38-MAPK* phosphorylation, and upregulation of TGF-β1/2 and fibronectin (fibronectin) in renal cells. GK-136901 also inhibits the proliferation of mouse pulmonary vascular cells under hypoxic conditions. GK-136901 is applicable to the research on the pathogenesis of type 2 diabetic nephropathy, high glucose-related renal lesions and pulmonary hypertension .

Cat. No.	Product Name	Target	Research Area

HY-P1435

NoxA1ds	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds can be used in the study of hypertension, atherosclerosis and tumors .

HY-P1435A

NoxA1ds TFA	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds TFA is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds TFA inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds TFA can be used in the study of hypertension, atherosclerosis and tumors .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702387

	NOX1 Protein, Human (Cell-Free, His) NADPH oxidase 1; Mitogenic oxidase 1; MOX-1; NADH/NADPH mitogenic oxidase subunit P65-MOX; NOH-1	Human	E. coli Cell-free
	The NOX1 protein contains two isoforms with different functions. NOH-1S acts as a voltage-gated proton channel, manages H(+) currents in quiescent phagocytes and tissues, affects cellular pH, and is inhibited by zinc. NOX1 Protein, Human (Cell-Free, His) is the recombinant human-derived NOX1 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.